Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

CONTEXT: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substa...

全面介绍

书目详细资料
Main Authors: Chortis, V, Taylor, A, Schneider, P, Tomlinson, J, Hughes, B, O'Neil, D, Libé, R, Allolio, B, Bertagna, X, Bertherat, J, Beuschlein, F, Fassnacht, M, Karavitaki, N, Mannelli, M, Mantero, F, Opocher, G, Porfiri, E, Quinkler, M, Sherlock, M, Terzolo, M, Nightingale, P, Shackleton, C, Stewart, P, Hahner, S, Arlt, W
格式: Journal article
语言:English
出版: 2013

相似书籍